Antimicrobial Agents Practice Questions

Q: A patient on indinavir treatment presents with jaundice. Detailed evaluation reveals that the elevated bilirubin is mainly the indirect fraction. What is the probable mechanism of indirect hyperbilirubinemia in this setting?

Decreased conjugation. ### Explanation **Correct Option: C. Decreased conjugation** Indinavir, a Protease Inhibitor (PI) used in HIV treatment, is well-known to cause asymptomatic **indirect (unconjugated) hyperbilirubinemia**. The underlying mechanism is the **potent inhibition of Uridine diphosphate-glucuronosyltransferase (UGT1A1)**, the enzyme responsible for conjugating bilirubin in the liver. This mimics the clinical presentation of **Gilbert Syndrome**. Since the bilirubin cannot be conjugated, it remains in the indirect form, leading to jaundice without significant elevation of transaminases or alkaline phosphatase. **Analysis of Incorrect Options:** * **A. Increased bilirubin production:** This typically occurs in states of massive cell turnover or ineffective erythropoiesis, which is not the mechanism for indinavir-induced jaundice. * **B. Decreased hepatocellular uptake:** While some drugs (like Rifampicin) can interfere with the uptake of bilirubin into hepatocytes via OATP transporters, Indinavir specifically targets the enzymatic conjugation step. * **D. Hemolysis:** Although hemolysis causes indirect hyperbilirubinemia, Indinavir does not typically cause red cell breakdown. In hemolysis, you would also expect low haptoglobin and elevated LDH, which are absent here. **High-Yield Clinical Pearls for NEET-PG:** * **Indinavir Side Effects:** Remember the triad: **Indirect Hyperbilirubinemia**, **Nephrolithiasis** (crystalluria—patients must stay hydrated), and **Lipodystrophy** (buffalo hump/insulin resistance). * **Atazanavir:** Another Protease Inhibitor that frequently causes indirect hyperbilirubinemia via the same UGT1A1 inhibition mechanism. * **Gilbert Syndrome Link:** Patients with pre-existing Gilbert Syndrome are at a much higher risk of developing visible jaundice when started on Indinavir or Atazanavir.

Q: Which of the following drugs, when administered in high doses, can cause convulsions?

Penicillin. **Explanation:** **1. Why Penicillin is the Correct Answer:** High doses of Penicillins, particularly **Penicillin G**, are well-known to be neurotoxic. The underlying mechanism is the **antagonism of GABA-A receptors** in the central nervous system. Since GABA is the primary inhibitory neurotransmitter, its blockade leads to neuronal hyperexcitability, which can manifest as myoclonus or generalized tonic-clonic **convulsions**. This risk is significantly increased in patients with **renal failure** (due to drug accumulation) or those with pre-existing seizure disorders. **2. Why Other Options are Incorrect:** * **Aminoglycosides (e.g., Gentamicin):** These are primarily associated with **ototoxicity** (vestibular and cochlear damage) and **nephrotoxicity** (acute tubular necrosis). They do not typically cause CNS excitation or seizures. * **Erythromycin (Macrolide):** The hallmark adverse effects of Macrolides include GI upset, **cholestatic jaundice** (especially with Erythromycin estolate), and **QT interval prolongation**. They are not associated with convulsions. **3. High-Yield Clinical Pearls for NEET-PG:** * **Other Antibiotics causing Seizures:** Apart from Penicillins, **Imipenem** (a Carbapenem) and **Fluoroquinolones** (e.g., Ciprofloxacin) are high-yield causes of drug-induced seizures. * **Imipenem vs. Meropenem:** Imipenem has a higher seizure potential than Meropenem; hence Meropenem is preferred in CNS infections like meningitis. * **Ceftriaxone:** While most Beta-lactams can cause seizures at very high doses, Ceftriaxone is more commonly noted for causing **biliary sludge** (pseudolithiasis). * **Management:** Drug-induced seizures are generally managed by discontinuing the offending agent and administering **Benzodiazepines**.

Q: Which of the following statements about terbinafine is FALSE?

It is used topically only.. **Explanation:** Terbinafine is an **allylamine** antifungal agent that plays a crucial role in treating superficial fungal infections. **1. Why Option D is the Correct Answer (The False Statement):** Terbinafine is **not** used topically only. It has excellent oral bioavailability and is highly lipophilic and keratophilic. When taken orally, it accumulates in high concentrations in the skin, sebum, and nails. This makes **oral terbinafine** the drug of choice for systemic treatment of fungal nail infections (onychomycosis) and extensive tinea corporis. **2. Analysis of Incorrect Options:** * **Option A (Restricted to dermatophytes):** While terbinafine has some activity against *Candida*, its clinical efficacy is primarily and significantly superior against **dermatophytes** (e.g., *Trichophyton*, *Epidermophyton*, and *Microsporum*). * **Option B (Effective in onychomycosis):** Due to its keratophilic nature, it remains in the nail plate for weeks even after stopping therapy. It is considered more effective than griseofulvin or itraconazole for fungal nail infections. * **Option C (Inhibits squalene epoxidase):** This is its primary mechanism of action. By inhibiting this enzyme, it prevents the conversion of squalene to lanosterol. This leads to a **deficiency of ergosterol** (essential for fungal cell membranes) and a **toxic accumulation of squalene**, which is fungicidal. **Clinical Pearls for NEET-PG:** * **Mechanism:** Inhibits Squalene Epoxidase (unlike Azoles, which inhibit 14-α demethylase). * **Nature:** It is **fungicidal** against dermatophytes (Azoles are mostly fungistatic). * **Side Effects:** Most common are GI upset and taste disturbances. Rarely, it can cause hepatotoxicity (monitor LFTs). * **Drug of Choice:** Oral terbinafine is the gold standard for **Onychomycosis**.

Q: All of the following drugs have activity against hepatitis EXCEPT:

Zidovudine. **Explanation:** The core concept tested here is the specificity of Nucleoside Reverse Transcriptase Inhibitors (NRTIs) for different viral polymerases. While many NRTIs are used for both HIV and Hepatitis B (HBV), **Zidovudine (AZT)** is exclusively an anti-retroviral agent with no clinical activity against the Hepatitis B virus. **1. Why Zidovudine is the correct answer:** Zidovudine was the first NRTI approved for HIV. It specifically inhibits the HIV reverse transcriptase enzyme. Unlike other drugs in its class, it does not effectively inhibit the HBV DNA polymerase. Therefore, it has no role in the treatment of any form of viral hepatitis. **2. Why the other options are incorrect:** * **Lamivudine (3TC):** A potent inhibitor of both HIV reverse transcriptase and HBV DNA polymerase. It was the first oral antiviral approved for Chronic Hepatitis B. * **Emtricitabine (FTC):** Structurally related to Lamivudine, it is highly effective against both HIV and HBV. It is frequently used in co-infected patients. * **Telbivudine:** An L-thymidine nucleoside analogue specifically indicated for the treatment of Chronic Hepatitis B. It is not used for HIV. **High-Yield Clinical Pearls for NEET-PG:** * **HBV + HIV Co-infection:** Drugs active against both include **Tenofovir (TDF/TAF)**, **Lamivudine**, and **Emtricitabine**. Tenofovir is currently the preferred backbone for co-infection. * **Entecavir:** A potent anti-HBV drug that should *not* be used as monotherapy in HIV-infected patients because it can select for the M184V mutation in HIV. * **Zidovudine Side Effects:** Remember the "3 Ms": **M**acrocytic anemia (bone marrow suppression), **M**yopathy, and **M**elanonychia (nail pigmentation).

Q: What is the drug of choice for urinary tract infections (UTIs) caused by Pseudomonas?

Ciprofloxacin. **Explanation:** **1. Why Ciprofloxacin is the Correct Answer:** *Pseudomonas aeruginosa* is a notorious Gram-negative pathogen known for its intrinsic resistance to many common antibiotics. **Ciprofloxacin**, a second-generation fluoroquinolone, is the drug of choice for oral treatment of pseudomonal UTIs. Its mechanism involves inhibiting **DNA gyrase (Topoisomerase II)** and **Topoisomerase IV**, preventing bacterial DNA replication. It is highly effective because it achieves high concentrations in the urine and possesses excellent bactericidal activity against most strains of *Pseudomonas*. **2. Why the Other Options are Incorrect:** * **Amoxicillin (Option A):** This is a penicillin that is easily degraded by beta-lactamases. *Pseudomonas* is naturally resistant to amoxicillin. * **Amoxiclav (Option B):** While Clavulanic acid protects amoxicillin from some beta-lactamases, it does not extend the spectrum to include *Pseudomonas*. * **Cefixime (Option C):** This is a 3rd-generation oral cephalosporin. While effective against many Enterobacteriaceae (like *E. coli*), it has **no activity** against *Pseudomonas*. **3. NEET-PG High-Yield Clinical Pearls:** * **Anti-Pseudomonal Cephalosporins:** Remember the "3b and 4" rule: **Ceftazidime** (3b) and **Cefepime** (4th gen) are the cephalosporins active against *Pseudomonas*. * **Anti-Pseudomonal Penicillins:** Piperacillin and Ticarcillin. * **Carbapenems:** Imipenem and Meropenem are active, but **Ertapenem** is the "exception" (it has no activity against *Pseudomonas*). * **Aminoglycosides:** Amikacin is generally the most potent aminoglycoside against *Pseudomonas*. * **Safety Note:** Fluoroquinolones like Ciprofloxacin are contraindicated in pregnancy and children due to the risk of **cartilage damage (arthropathy)**.

Q: In the treatment of Pseudomonas infections, carbenicillin is frequently combined with which of the following agents?

Gentamicin. The correct answer is **Gentamicin**. This combination is a classic example of **pharmacodynamic synergy** used in the management of serious *Pseudomonas aeruginosa* infections [1]. **Why Gentamicin is correct:** Carbenicillin (an antipseudomonal penicillin) and Gentamicin (an aminoglycoside) work together through a synergistic mechanism: 1. **Cell Wall Inhibition:** Carbenicillin inhibits bacterial cell wall synthesis, which increases the permeability of the bacterial membrane [3]. 2. **Enhanced Entry:** This structural damage allows Gentamicin to enter the bacterial cell more easily, where it binds to the 30S ribosomal subunit to inhibit protein synthesis [3]. *Note: These drugs should never be mixed in the same IV bottle/syringe as they are chemically incompatible (aminoglycosides are basic and penicillins are acidic), leading to mutual inactivation.* **Why other options are incorrect:** * **A & D (Penicillin/Amoxicillin):** These are narrow or broad-spectrum penicillins that lack significant activity against *Pseudomonas*. Combining two beta-lactams generally does not provide synergy and may increase the risk of toxicity. * **C (Ciprofloxacin):** While Ciprofloxacin has antipseudomonal activity, it is not the standard "textbook" synergistic partner for carbenicillin in the way aminoglycosides are. **NEET-PG High-Yield Pearls:** * **Synergy Rule:** Always remember: **Cell wall synthesis inhibitor + Aminoglycoside = Synergy.** (e.g., Penicillin + Gentamicin for Enterococcal endocarditis) [2]. * **Antipseudomonal Penicillins:** Include Carboxypenicillins (Carbenicillin, Ticarcillin) and Ureidopenicillins (Piperacillin). Piperacillin is currently the most potent. * **Incompatibility:** Aminoglycosides are physically incompatible with beta-lactams *in vitro*. Administer them at different sites or times.

Q: The HIV fusion inhibitor, enfuvirtide, acts at which site?

Gp 41. **Explanation:** **Enfuvirtide** is a unique antiretroviral drug classified as a **Fusion Inhibitor**. To understand its mechanism, one must recall the steps of HIV entry into the CD4+ T cell [3]: 1. **Attachment:** Viral **gp120** binds to the host **CD4 receptor**. 2. **Co-receptor binding:** gp120 undergoes a conformational change to bind to **CCR5 or CXCR4** [2]. 3. **Fusion:** The transmembrane subunit **gp41** undergoes a structural change (forming a six-helix bundle), which pulls the viral and host membranes together, allowing the viral capsid to enter the cell. **Enfuvirtide** mimics a segment of gp41. It binds to the HR1 (heptad repeat 1) region of **gp41**, preventing the necessary conformational change required for membrane fusion [1]. **Analysis of Incorrect Options:** * **Gp 120:** This is the surface subunit responsible for initial attachment. Drugs like **Fostemsavir** (attachment inhibitor) and **Ibalizumab** (post-attachment inhibitor) target this stage, not enfuvirtide. * **P24:** This is a structural protein that forms the viral **capsid**. It is used as a diagnostic marker in early HIV infection (p24 antigen assay) but is not the target of enfuvirtide. * **CXCR4:** This is a host co-receptor [3]. **Maraviroc** is the drug that acts at the entry stage by binding to the **CCR5** co-receptor (it does not target CXCR4) [2]. **High-Yield NEET-PG Pearls:** * **Route of Administration:** Enfuvirtide is the only HIV drug administered **subcutaneously** (it is a synthetic peptide) [1]. * **Side Effects:** Almost 100% of patients develop **injection site reactions** (nodules, erythema). * **Indication:** Used as "salvage therapy" in treatment-experienced patients with multi-drug resistant HIV [1]. * **Mnemonic:** En**fu**virtide prevents **Fu**sion by targeting gp**41** (think: "41 looks like a needle/spike used for fusion").

Q: Cilastatin is combined with which of the following to increase its duration?

Imipenem. **Explanation:** **1. Why Imipenem is the Correct Answer:** Imipenem is a broad-spectrum carbapenem antibiotic. When administered alone, it is rapidly inactivated in the body by the enzyme **Dehydropeptidase-I (DHP-I)**, located in the brush border of the proximal renal tubules. This metabolism results in low urinary concentrations and the formation of potentially nephrotoxic metabolites. **Cilastatin** is a specific, reversible inhibitor of DHP-I. It is combined with Imipenem to: * Prevent its renal degradation, thereby increasing its plasma half-life and duration of action. * Ensure high therapeutic concentrations in the urine. * Reduce the risk of nephrotoxicity. **2. Why Other Options are Incorrect:** * **Carbenicillin & Penicillin G:** These are penicillins. Their duration of action is typically extended by combining them with **Probenecid**, which inhibits their renal tubular secretion, or by using repository forms (e.g., Benzathine Penicillin). They are not metabolized by DHP-I. * **Cefoperazone:** This is a third-generation cephalosporin. It is primarily excreted via bile and does not require a DHP-I inhibitor. It is frequently combined with **Sulbactam** (a beta-lactamase inhibitor) to enhance its spectrum against resistant bacteria. **3. High-Yield Clinical Pearls for NEET-PG:** * **Mnemonic:** "The kill is lastin' with Cilastatin" (It makes Imipenem last longer). * **Newer Carbapenems:** Meropenem, Ertapenem, and Doripenem are **resistant to DHP-I**; therefore, they do *not* require co-administration with Cilastatin. * **Adverse Effect:** Imipenem-Cilastatin carries a higher risk of **seizures**, especially in patients with renal failure or pre-existing CNS lesions. * **Spectrum:** Imipenem is the drug of choice for *Enterobacter* infections and mixed aerobic/anaerobic infections.

Q: What is the latest drug used for the treatment of multidrug-resistant tuberculosis (MDR-TB) patients?

Bedaquiline. **Explanation:** **Bedaquiline** is the correct answer as it represents a paradigm shift in the management of Multidrug-Resistant Tuberculosis (MDR-TB). It is a diarylquinoline that inhibits the enzyme **mycobacterial ATP synthase**, effectively "starving" the bacteria of energy. It was the first new TB drug class approved by the FDA in over 40 years and is now a core component of the WHO-recommended all-oral shorter regimens for MDR-TB. **Analysis of Options:** * **Amithiozone (Thiacetazone):** An older bacteriostatic drug rarely used today due to severe adverse effects, including Stevens-Johnson Syndrome, especially in HIV-positive patients. * **Capreomycin:** A cyclic peptide antibiotic (injectable) formerly used as a second-line agent. Current WHO guidelines prioritize all-oral regimens, moving injectables like Capreomycin to "Group C" (last resort) or phasing them out entirely. * **Linezolid:** While highly effective and used in MDR-TB regimens (Group A), it is an oxazolidinone originally developed for Gram-positive cocci. Bedaquiline is more "novel" in its specific indication and mechanism for TB. **High-Yield Clinical Pearls for NEET-PG:** * **Mechanism of Action:** Inhibits the proton pump of ATP synthase (encoded by the *atpE* gene). * **Black Box Warning:** Bedaquiline can cause **QT interval prolongation**. It should be monitored closely with ECGs, especially if co-administered with Clofazimine or Delamanid. * **Metabolism:** It is metabolized by **CYP3A4**; hence, its levels are decreased by Rifampicin (a potent inducer). * **BPaL Regimen:** A modern, highly effective 6-month regimen for highly resistant TB consisting of **B**edaquiline, **P**retomanid, and **L**inezolid.

Q: All of the following are direct-acting antiviral agents for Hepatitis C virus (HCV) infections except?

Entecavir. The core concept tested here is the classification of antiviral drugs based on their target virus. **Entecavir** is a potent nucleoside analog (guanosine analog) used primarily for the treatment of **Chronic Hepatitis B Virus (HBV)** infection [2]. It works by inhibiting HBV DNA polymerase [2]. It has no clinical efficacy against the Hepatitis C Virus (HCV) [1]. **Direct-Acting Antivirals (DAAs) for HCV** are classified based on their molecular targets within the HCV replication cycle [1]: * **NS5A Inhibitors (Suffix "-asvir"):** **Ledipasvir** (Option A) belongs to this class. These drugs inhibit the NS5A replication complex. * **NS5B Polymerase Inhibitors (Suffix "-buvir"):** **Beclabuvir** (Option B) is a non-nucleoside NS5B polymerase inhibitor. Other examples include Sofosbuvir. * **NS3/4A Protease Inhibitors (Suffix "-previr"):** **Paritaprevir** (Option D) belongs to this class. These drugs prevent the cleavage of the viral polyprotein. **High-Yield Clinical Pearls for NEET-PG:** 1. **Mnemonic for HCV DAAs:** * **P**revir = **P**rotease (NS3/4A) * **A**svir = NS5**A** * **B**uvir = NS5**B** (Polymerase) 2. **Entecavir** is a first-line agent for HBV due to its high genetic barrier to resistance, unlike Lamivudine [2]. 3. **Ribavirin** is an older, indirect-acting antiviral used for HCV, but it is not classified as a "Direct-Acting Antiviral" (DAA) [3]. 4. **Sofosbuvir** is the "backbone" of most modern HCV regimens and is a nucleotide NS5B inhibitor.

Question 1

A patient on indinavir treatment presents with jaundice. Detailed evaluation reveals that the elevated bilirubin is mainly the indirect fraction. What is the probable mechanism of indirect hyperbilirubinemia in this setting?

Accepted Answer

Decreased conjugation

Answer

Increased bilirubin production

Answer

Decreased hepatocellular uptake

Answer

Hemolysis

Question 2

Which of the following drugs, when administered in high doses, can cause convulsions?

Accepted Answer

Penicillin

Answer

Aminoglycosides

Answer

Erythromycin

Answer

All of the above

Question 3

Which of the following statements about terbinafine is FALSE?

Accepted Answer

It is used topically only.

Answer

Its activity is restricted to dermatophytes.

Answer

It is effective in onychomycosis.

Answer

It inhibits squalene epoxidase.

Question 4

All of the following drugs have activity against hepatitis EXCEPT:

Accepted Answer

Zidovudine

Answer

Lamivudine

Answer

Emtricitabine

Answer

Telbivudine

Question 5

What is the drug of choice for urinary tract infections (UTIs) caused by Pseudomonas?

Accepted Answer

Ciprofloxacin

Answer

Amoxicillin

Answer

Amoxiclav

Answer

Cefixime

Question 6

In the treatment of Pseudomonas infections, carbenicillin is frequently combined with which of the following agents?

Accepted Answer

Gentamicin

Answer

Penicillin

Answer

Ciprofloxacin

Answer

Amoxicillin

Question 7

The HIV fusion inhibitor, enfuvirtide, acts at which site?

Accepted Answer

Gp 41

Answer

Gp 120

Answer

P24

Answer

CXCR4

Question 8

Cilastatin is combined with which of the following to increase its duration?

Accepted Answer

Imipenem

Answer

Carbenicillin

Answer

Cefoperazone

Answer

Penicillin G

Question 9

What is the latest drug used for the treatment of multidrug-resistant tuberculosis (MDR-TB) patients?

Accepted Answer

Bedaquiline

Answer

Amithiozone

Answer

Capreomycin

Answer

Linezolid

Question 10

All of the following are direct-acting antiviral agents for Hepatitis C virus (HCV) infections except?

Accepted Answer

Entecavir

Answer

Ledipasvir

Answer

Beclabuvir

Answer

Paritaprevir

Antimicrobial Agents — MCQs

Antimicrobial Agents — MCQs

On this page

Practice by Chapter

Want unlimited practice?